Sangui Biotech Cash And Equivalents vs. Revenue

SGBI Stock  USD 0  0.00  0.00%   
Considering the key profitability indicators obtained from Sangui Biotech's historical financial statements, Sangui Biotech International may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Sangui Biotech's ability to earn profits and add value for shareholders.
For Sangui Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sangui Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sangui Biotech International utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sangui Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sangui Biotech International over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Sangui Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangui Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangui Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sangui Biotech Inter Revenue vs. Cash And Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sangui Biotech's current stock value. Our valuation model uses many indicators to compare Sangui Biotech value to that of its competitors to determine the firm's financial worth.
Sangui Biotech International is currently regarded as top stock in cash and equivalents category among its peers. It also is currently regarded number one company in revenue category among its peers totaling about  2.27  of Revenue per Cash And Equivalents. Comparative valuation analysis is a catch-all model that can be used if you cannot value Sangui Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sangui Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Sangui Revenue vs. Cash And Equivalents

Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Sangui Biotech

Cash

 = 

Bank Deposits

+

Liquidities

 = 
30.47 K
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Sangui Biotech

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
69.19 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Sangui Revenue vs Competition

Sangui Biotech International is currently regarded number one company in revenue category among its peers. Market size based on revenue of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 2.7 Billion. Sangui Biotech adds roughly 69,190 in revenue claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.

Sangui Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sangui Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sangui Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Sangui Biotech's change in net profit over the period of time. It can combine multiple indicators of Sangui Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.

Sangui Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sangui Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sangui Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sangui Biotech's important profitability drivers and their relationship over time.

Use Sangui Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangui Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangui Biotech will appreciate offsetting losses from the drop in the long position's value.

Sangui Biotech Pair Trading

Sangui Biotech International Pair Trading Analysis

The ability to find closely correlated positions to Sangui Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangui Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangui Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangui Biotech International to buy it.
The correlation of Sangui Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangui Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangui Biotech Inter moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangui Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sangui Biotech position

In addition to having Sangui Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Funds Thematic Idea Now

Tech Funds
Tech Funds Theme
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Sangui Pink Sheet

To fully project Sangui Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sangui Biotech Inter at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sangui Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential Sangui Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sangui Biotech investors may work on each financial statement separately, they are all related. The changes in Sangui Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sangui Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.